NEW YORK ─ Cancer diagnostics firm Epredia on Monday announced that it has entered into a distribution agreement for Aiforia's artificial intelligence-based pathology software.
Under the terms of the agreement, Portsmouth, New Hampshire-based Epredia will distribute Aiforia's portfolio of preclinical and clinical pathology tools globally, with exclusive rights in Japan, Germany, the UK, Italy, Spain, Sweden, Norway, Denmark, Iceland, France, and the US.
Financial and other terms of the agreement were not disclosed.
Starting this summer, Aiforia's portfolio of AI products will be available as part of Epredia's digital pathology portfolio, which includes its CE-marked 3DHistech P1000 WSI scanner, Epredia said.
Helsinki-based Aiforia recently announced CE marking for its Clinical AI Model for Breast Cancer: Ki67, part of the company's Clinical Suites, which it is developing for the diagnosis of highly prevalent cancers, including breast, lung, and prostate cancer. Ki67 is a biomarker used for breast cancer diagnosis.
"With their global presence in the pathology market and our expertise in delivering AI-based solutions for pathologists, Epredia is the ideal commercial partner to help us broaden the international reach of Aiforia's powerful AI software to pathologists working in clinical diagnostics and preclinical drug development," Aiforia CEO Jukka Tapaninen said in a statement.